0001193125-26-221890
SEC filingRevenue grew 43% to $12.1M driven by neurosurgery products and IRRAS acquisition, but net loss widened to $9.6M on higher expenses.
For Q1 2026, ClearPoint Neuro reported total revenue of $12.1 million, a 43% increase from $8.5 million in Q1 2025. The growth was fueled by a 66% surge in product revenue to $8.8 million, while service and other revenue grew modestly by 4% to $3.3 million. Gross profit rose 51% to $7.8 million, and gross margin improved to 64% from 60% in the prior-year period, primarily due to lower excess and obsolete inventory charges. Despite top-line growth, net loss widened 59% to $9.6 million from $6.0 million, driven by significant increases in operating expenses and new interest expense. Research and development costs rose 34% to $4.5 million, sales and marketing expenses jumped 75% to $6.7 million (reflecting the expanded commercial team from the IRRAS acquisition), and general and administrative expenses increased 22% to $5.0 million. Interest expense of $1.4 million, absent in the prior year, resulted from notes payable issued in May and November 2025.
ClearPoint reports three revenue segments. Biologics and drug delivery revenue edged up 2% to $4.8 million, driven by disposable product sales but flat services and license fees. The segment, which includes preclinical and clinical support for pharma partners, remains heavily dependent on partner trial progression. Neurosurgery navigation and therapy revenue surged 80% to $5.9 million, driven by sales of the IRRA flow system (acquired in Q4 2025) and the new ClearPoint Navigation Software Version 3.0, which boosted operating room procedural volumes. Capital equipment and software revenue soared 177% to $1.4 million from $0.5 million, reflecting increased placements of ClearPoint navigation capital, IRRA flow control units, and Prism laser systems. The dramatic growth in these two segments highlights the transformative impact of the IRRAS acquisition and the company's push into operating room-based procedures.
Management expects revenue to grow further due to the larger combined organization, expanded product offerings, and increased customer reach both domestically and internationally. However, no specific quantitative guidance is provided. The company anticipates continued investments in R&D to develop devices for CNS therapeutics, expand into operating room and therapeutics spaces, and support the IRRA flow product portfolio. Sales and marketing expenses are expected to increase further with the larger commercial team. ClearPoint ended Q1 2026 with $35.6 million in cash and equivalents, which management believes is sufficient to support operations and obligations for at least the next twelve months. The company may pursue additional equity or debt financing to fund working capital and other needs. Key risks include the commercial success of partner therapies, market adoption of new products, and macroeconomic headwinds such as inflationary pressures and tariffs.
As of March 31, 2026, ClearPoint Neuro held $35.6 million in cash and cash equivalents, down from $45.9 million at December 31, 2025, reflecting operating cash burn of $8.0 million in Q1. The company has an accumulated deficit of $226.5 million. Total assets amount to $93.4 million, with $54.9 million in current assets. The company has $49.6 million in long-term notes payable (net of discounts and costs), with an effective interest rate of 11.3%. Management has concluded that existing cash is sufficient for at least the next twelve months from the filing date.
The company has operating lease obligations for its Solana Beach headquarters (expiring December 2026), Carlsbad office/manufacturing (ending May 2033), a San Diego expansion (11-year term starting 2025-2026), and an IRRAS-assumed lease (expiring April 2031). Aggregate lease cost was $0.5 million in Q1 2026. No other material purchase commitments or contractual obligations were disclosed.
Capital allocation in Q1 2026 centered on capital expenditures of $0.6 million for property and equipment. No share repurchases or dividends were declared. The company did not issue new debt in Q1 2026; the existing debt facility (2025 NPA) has up to $105 million capacity, with $51.4 million principal outstanding. Debt service includes quarterly interest (50% paid-in-kind through early 2027) and a revenue participation component beginning January 2027.
The company operates in one reportable segment. Revenue for Q1 2026 totaled $12.1 million, broken down as: biologics and drug delivery ($4.8M), neurosurgery navigation and therapy ($5.9M), and capital equipment and software ($1.4M). Geographic mix is not disclosed at the note level, but the company states that operations are predominantly in the United States.